Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04513639
Title The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
Acronym REMNANT
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Oslo University Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries NOR


No variant requirements are available.